R. Lor Randall, MD, FACS, of UC Davis Health, opens this OncLive Insights discussion on tenosynovial giant cell tumor (TGCT) with Dale R. Shepard, MD, PhD, of Cleveland Clinic, and Alexander B. Christ, MD, of UCLA Health.
Back
The Evolving Treatment Landscape in TGCT
R. Lor Randall, MD, FACS, of UC Davis Health; Dale R. Shepard, MD, PhD, of Cleveland Clinic; and Alexander B. Christ, MD, of UCLA Health, discuss how tenosynovial giant cell tumor (TGCT) is recognized and referred, how they choose between surgery and colony-stimulating factor 1 receptor (CSF1R) inhibitors, what the phase 3 MANEUVER trial showed for the investigational agent pimicotinib, and how long patients may need treatment.
The Evolving Treatment Landscape in TGCT
Episodes
All
All
Alexander B. Christ, MD, of UCLA Health, and Dale R. Shepard, MD, PhD, of Cleveland Clinic, explain how they choose between surgery and systemic therapy for diffuse tenosynovial giant cell tumor (TGCT) in a discussion moderated by R. Lor Randall, MD, FACS, of UC Davis Health.
Advertisement
Advertisement
Trending on OncLive
1
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
2
Five Under 5: Top Oncology Videos for the Week of 10/12
3
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
4
Early-Phase INCA33890 Data Lay the Foundation for Phase 3 Combination Research in MSS CRC
5